An RNA containing 2'-amino pyrimidines has been isolated using in vitro selection techniques that specifically and avidly (apparent Ka ,'-,30 nM) binds a mouse monoclonal antibody called MA20. This 2'-amino-derivatized RNA is at least 10,000-fold more stable than unmodified RNA in serum, and can act as a decoy and block MA20 binding to its natural antigen, the human insulin receptor, on lymphocytes. Furthermore, this RNA decoy can inhibit MA20-mediated downmodulation of insulin receptor expression on human lymphocytes in culture by up to 90%. Surprisingly, the decoy RNA cross-reacts with autoantibodies from patients with extreme insulin resistance and can inhibit these antiinsulin receptor antibodies from downmodulating insulin receptor expression by up to 80% without impeding insulin binding to its receptor. These results suggest that in vitro--selected decoy RNAs may be able to specifically and selectively block oligoclonal autoimmune responses to self-antigens in patients with autoimmune diseases.
A utoimmune diseases are often caused by abnormal targeting of self-antigens by autoantibodies (1) . A small "decoy" ligand could potentially interrupt this process if it specifically and avidly bound the autoantibodies and blocked them from interacting with their target antigen. A small peptide decoy seems the most obvious choice for such an inhibitor because a peptide should be able to structurally mimic the autoantigenic epitope on a self-protein. Unfortunately, isolation of small peptides that bind avidly to target proteins has been difficult, probably because short peptides cannot adopt stably folded structures very readily (2) . By contrast, short RNA molecules can form fairly stable structures through basepairing interaction (3), and RNA decoys have been reported that avidly bind and block a variety of proteins (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Expression of TAR and RRE decoy RNAs has been shown to render CD4 + T cells resistant to HIV replication by inhibiting the functions of the RNAbinding proteins tat and rev (8) (9) (10) (11) (12) . Furthermore, by using in vitro selection techniques, "designer" decoy RNAs have been isolated from large pools of random RNA molecules that bind with high affinity and specificity to several proteins, including a few that do not naturally interact with nucleic acids (13, (15) (16) (17) (18) (19) (20) (21) (22) .
We previously identified a designer decoy RNA that binds and blocks the mAb, MA20 (18) . This antibody naturally recognizes the main immunogenic epitope on the human insulin receptor (23) that elicits autoantibodies in patients with severe insulin resistance (type B) (24) (25) (26) . A1-though this RNA was shown to be able to block MA20 binding to purified insulin receptors in solution in a test tube, we realized that the therapeutic utility of such a decoy RNA would be limited by its short half-hfe in the presence of serum nucleases. In addition, it was unclear if an RNA decoy made against MA20 could block an oligoclonal autoantibody response to the immunogenic epitope on the insulin receptor. Therefore, we sought to isolate a nuclease-resistant decoy RNA specific for MA20 and to determine if this RNA could inhibit patient autoantibodies from binding the insulin receptors on human cells in culture.
To generate nuclease-resistant RNA decoys, in vitro selection was performed using an RNA library that contains 2'-amino-modified pyrimidine nucleotides. Changing the 2' position on the pyrimidines of an RNA from a hydroxyl to an amino group substantially increases the stability of RNA in serum (27) . The modified pyrimidine nucleotides are compatible with in vitro selection procedures because 2'-amino-2'-deoxypyrimidine triphosphates can be incorporated into RNA by T7 RNA polymerase (28) , and RNA with 2'-amino pyrimidines can serve as substrates for AMV reverse transcriptase. Using similar methodology, RNase-resistant ligands with 2'-amino pyrimidines that bind human neutrophil elastase (17, 20) , basic fibroblast growth factor (21) , or vascular permeability factor/vascular endothelial growth factor (22) have been identified.
Here, we report the isolation of a nuclease-resistant decoy RNA that specifically and avidly binds the MA20 anti-body and cross-reacts with autoantibodies from patients with severe insulin resistance. Furthermore, the decoy RNA can block MA20 and patient autoantibodies from binding to and downmodulating expression of insulin receptors on human lymphocytes in culture without impeding insulin binding.
Materials and Methods
Antibodies and Cells. An mAb, MA20, was kindly provided by Ira Goldfine and Betty Maddux (University of California, San Francisco, CA). An mAb, 83-7, was a gift from Kenneth Siddle (Addenbrooke's Hospital, University of Cambridge, Cambridge, UK). Serum samples from three patients with severe insulin resistance type B, called B7, B10, and Bd, were provided by Domenico Accili and Simeon Taylor (National Institutes of Health, Bethesda, MD). IM-9 human lymphoblasts (ATCC 159-CCL) express high levels of insulin receptors on their plasma membranes (29) and were used in insulin receptor downregulation experiments.
Selection Procedure. A random pool of RNA oligonucleotides was generated by in vitro transcription of synthetic DNA templates using 2' amino derivatized CTP and UTP (Amersham, Arlington Heights, IL) and normal GTP and ATP in the reaction. The sequence of the resulting RNA is 5'-GGGAGAGCGGAA-GCGUGCUGGGCCN40CAUAACCCAGAGGUCGAUGGA-UCCCCCC-3', where N40 represents 40 nucleotides (nts) 1 with eqimolar incorporation of A, G, C, and U at each position. First, the RNA library (30 Ixg) was incubated with 5 txl normal mouse IgGs (1 mg/ml) in 100 txl binding buffer (30 mM Tris-HC1, pH 7.5, 150 mM NaC1, 10 mM MgC12, 2 mM dithiothreitol, and 1% BSA) for 30 min at room temperature with shaking. Then, 20 p~l of goat anti-mouse IgG-coated magnetic beads (Dynal, Oslo, Norway) or 20 fxl of protein G-Sepharose beads (Pharmacia Biotech, Piscataway, NJ) were added to the binding reaction and incubated for an additional 30 rain. Antibody-RNA complexes were immunoprecipitated and discarded to remove RNAs that bind to the constant region of the antibodies or adhere nonspecifically to the beads. The precleared supernatant was transferred to a new tube and incubated with 5 txl of mouse mAb MA20 (0.5 mg/ml) for 30 min at room temperature. The mAb-RNA complexes were then immunoprecipitated using magnetic beads or protein G-Sepharose beads as mentioned above, and the pellets were washed three times with 0.5 ml of the binding buffer. RNA was eluted from the pellets by a 5-min incubation with 100 btl of 0.1 M EDTA and phenol extraction. The RNA eluate was then applied to a Sephadox G-50 spin column to remove EDTA and salts, and reverse-transcribed for 30 min at room temperature using avian myeloblastosis virus reverse transcriptase (RT; Boehringer Mannheim, Indianapolis, IN) and a 28-nt DNA primer complementary to the fixed 3' sequence of the RNA pool. The RT was then inactivated by heating the sample to 95~ for 5 min. The resulting cDNAs were amplified by PCR for 20 cycles using Taq DNA polymerase (Perkin-Elmer Cetus, Norwalk, CT) and a second DNA primer which was identical to the fixed 5'-end of the RNA pool and contained the 17-nt promoter sequence for T7 RNA polymerase. The amplified DNA was phenol extracted, ethanol precipitated, and resuspended in 25 I~1 of TE (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). 40% of this DNA template was t Abbreviation used in this paper: nts, nucleotides. transcribed in vitro with T7 RNA polymerase and the 2'-aminomodified mix of NTPs to generate RNA for the next round of selection. Subsequent rounds were performed in the same manner using either 50% (rounds 1-9) or 20% (rounds 10-12) of the transcribed RNA. Goat anti-mouse IgG-coated beads were used on odd-numbered and protein G-Sepharose beads on even nun> bered rounds of selection. From round 10, MA20 concentration was reduced fivefold, and mAb-RNA pellets were washed five or more times. After 12 rounds of selection, the amplified DNA was cloned and several clones were sequenced. Monitoring Insulin Receptor Downmodulation on IM-9 Cells. Insulin receptor downregulation was assayed as described previously (23) , with a few modifications. 1.0 X 104 IM-9 cells were resuspended in 75 ILl of media (DMEM) with 10 mM MgC12, 1% BSA, and 10% FBS. MA20 (1 riM), autoantibodies or insulin (1 p~M) were incubated in 25 >1 binding buffer with the original amino RNA pool, 2'-amino RNA No. 1, or no RNA ~br 3{) min at room temperature. These mixtures were then added to IM-9 cells and incubated at 37~ for 15 min. Next, the cells were washed twice with a phosphate buffer, pH 6.0, containing 154 mM NaC1 and 0.1% BSA for 30 rain at 30~ to remove receptor-bound ligands (23) . To quantitate the number of insulin receptors remaining on the cell surface, the cells were resuspended in 100 p~l of 100 m M Hepes buffer, pH 7.8, containing 120 mM NaC1, 1.2 m M MgSO4, 1 m M EDTA, 15 m M sodium acetate, 10 mM glucose, and 1% BSA, and incubated with 150 pM 12sI-insulin for 70 min at 15~ The cells were pelleted and washed twice with 10 m M Tris-HC1 buffer, pH 7.8, containing 154 m M NaC1 at 4~ The washed cells were pelleted again and the radioactive 12sI-insttlin bound to them was determined using a "/5,000 counter (Packard Instruments, Meriden, CT). Incubation of IM-9 cells with 1 nM of MA20 by itselfreproducibly reduced insulin receptor expression by '--~50% (data not shown). This level of antigenic downregulation was considered 100%, and other values were normalized to this amount. Because 10 m M MgC12 is optimal for the binding of the selected R N A to MA20 in vitro, cell culture experiments were performed in media containing 10 m M MgC12. For antigenic downregulation experiments involving patient autoantibodies, patient serum or insulin was added to IM-9 cells at concentrations determined to engender similar levels of antigenic downregulation as 1 nM o f M A 2 0 : 1 Ixl of a 1:25 dilution of B7, 1 ILl of a 1:12 dilution of B10, 1 ~1 of undiluted Bd sera, or 1 ~M of insulin (data not shown). mouse IgGs (Fig. 1 B) . Furthermore, this binding was independent of the type of beads used to immunoprecipitate the M A 2 0 -R N A complexes (Fig. 1 B) . In addition, the 2 ' -a m i n o pool R N A does not nonspecifically bind to MA20 (Fig. 1 B, lanes 8-11) .
Results

Isolation of Nuclease-resistant R N A s That Specifically
To confirm that 2 ' -a m i n o R N A No. 1 specifically binds the MA20 antibody, a gel retardation assay was developed. As shown in Fig. 1 C, 2 ' -a m i n o R N A No. 1 efficiently forms a "shifted" nucleoprotein complex with MA20, but not with normal mouse IgGs. Formation of this nucleoprotein complex can be blocked by addition of a 10,000-fold excess of unlabeled 2'-amino R N A No. 1, but not by a nonspecific competitor, such as the original 2 ' -a m i n o pool R N A (Fig. 1 C, lanes 4 and 5) .
As a working model, the most stable secondary structure of 2 ' -a m i n o R N A No. 1 was predicted using the M U L -FOLD program (30) , and is shown in Fig. 2 A. In this folded structure, the 34-nt-long sequence, derived from the randomized region of the R N A library, is predicted to form basepairing interactions with the defined sequences that flank the random region in the 2'-amino R N A pool. To begin to test the validity of this predicted structure, as well as to determine if a shortened version of 2'-amino R N A No. 1 could be made that would still bind MA20, a series of truncated R N A s were generated and tested for antibody binding (Fig. 2 B) . To investigate the structural significance of the 2 ' -a m i n o groups on the pyrimidine nucleotides, selected R N A No. 1 was generated with 2'-hydroxyl pyrimidines and tested for binding to the MA20 antibody. As shown in Fig. 2 C, alteration of the 2' position disrupted the interaction between R N A No. 1 and MA20. Similarly, the 2' position appears to be critical for binding of our selected u n m o d ified R N A (18) to MA20. Changing the 2' position on the pyrimidines of this R N A from hydroxyls to aminos yielded a modified R N A that did not bind MA20 (Fig. 2 C) . Thus, the 2' position on both selected R N A s appears to be important for proper R N A folding and MA20 binding.
To estimate the equilibrium Kd for the interaction between 2 ' -a m i n o R N A No. 1 and MA20, a gel retardation assay was used (Fig. 3 A) . Trace amounts of radiolabeled R N A were incubated with increasing amounts of antibody and complexes separated on nondenaturing acrylamide gels. The same apparent K a of,'o30 n M was detected at three different concentrations of 2'-amino R N A No. 1 (Fig. 3 B) . Thus, selected 2'-amino R N A No. 1 binds fairly avidly to the MA20 antibody.
Even though the 2'-amino R N A No. 1 specifically and avidly binds MA20, this decoy would be of little therapeu- , 10{t nM) . The antibody-RNA complexes were imnmnoprecipitated and analyzed on an 8% polyacrylamide gel with urea. Lane a contains one-fifth of the amount of radiolabeled RNA that was incubated with the antibody. (C) The 2' position on the pyrimidine of the selected RNAs is important for antibody binding. Internally radiolabeled RNAs (2.5 nM) were incubated with normal mouse IgGs (lane 2, 125 nM) or MA20 (lane 3, 125 nM). RNAs immunoprecipitated by these antibodies were electrophoresed on a 6"/,, polyacrylamide gel with urea. Lane 1 contains one fifth of the amount of input RNA that was used in the immunoprecipitation reaction. The 2'-amino RNA No. 1 was made with either 2'-amino pymnidines (NHi/NH2*) or 2'-hydroxyl pyrinlidines (NH2/OH*). The 2'-hydroxyl RNA No. 9, which we previously described (18) , was made with either 2'-hydroxyl pyrimidines (OH/OH*) or 2'-amino pyrimidines (OH/NH2*).
tic utility if the R N A is quickly degraded by serum nucleases. Therefore, the stability of the 2'-amino R N A No. 1 in serum was measured (Fig. 4) . In 10% human sermn, R N A with 2'-hydroxyl groups (unmodified R N A ) was 
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e~. fairly stable in serum and that it could block MA20 binding to the insulin receptors expressed on IM-9 cells in serumfree conditions, we wanted to determine if this decoy RNA could protect cells from MA20 in culture media containing serum. Incubation of IM-9 cells with the MA20 antibody has been shown to cause a dose-and time-dependent decrease in the number of insulin receptors present on the surface of these cells (33) . This process, termed antigenic downregulation, can be easily monitored by determining the ability of the cells to bind 12+I-insulin (33). To determine if 2'-amino RNA No. 1 could protect cells from the effects of MA20 and inhibit antibody-mediated downregulation of insulin receptor expression, IM-9 cells were incubated with MA20 in the presence or absence of U-amino RNA No. 1. As shown in Fig. 6 A, a nonspecific RNA competitor, such as the original 2'-amino RNA pool, could not inhibit MA20-mediated downregulation of insulin receptor expression. However, decoy 2'-amino RNA No. 1 protected IM-9 cells from MA20 and inhibited antigenic downregulation by 75%. Furthermore, 2'-amino RNA No. 1-mediated inhibition of antigenic downregulation was dose dependent with an EDs0 of~0.6 IzM (Fig. 6  B) . A maximum inhibition of 80-90% was obtained at the highest doses tested. Thus, this nuclease-resistant decoy RNA can protect cells from the MA20 antibody in the presence of serum nucleases. R.NA No. 1 would also bind any o f the antiinsulin receptor autoantibodies from these patients. Therefore, an irmnunoprecipitation experiment was performed using radiolabeled 2'-amino R N A No. 1 and antibodies from sera of three different patients called B7, B10, and Bd. As shown in Fig.  7 A, all three of the autoimmune sera were found to contain antibodies that can bind and immunoprecipitate 2'-amino R N A No. 1. In contrast, the selected R N A was not precipitated by normal mouse IgGs, the 83-7 mAb (26, 31, 32) , or antibodies from normal human serum. Thus, 2'-amino R N A No. 1 appears to specifically cross-react with some fraction of the patients' autoantibodies.
%
This result raised the intriguing possibility that selected 2'-amino R N A No. 1 may resemble or mimic the structure of the main antigenic epitope on the human insulin receptor. If this were indeed the case, then one would predict that such a mimotope should be able to block a significant fraction of the patient autoantibodies from binding insulin receptors on the surface o f human cells. To test this hypothesis, we evaluated the ability o f 2 ' -a m i n o R N A No. 1 to protect cells from the effects o f the three autoimmune sera, B7, B10, and Bd. Incubation o f IM-9 cells with the patient sera was shown to cause a dose-and time-dependent decrease in insulin receptor expression, as monitored by the subsequent inability of these cells to bind 125I-insulin (data not shown). Addition o f selected 2'-amino R N A No. 1 protected the cells from the autoantibodies in the patient sera and inhibited downmodulation of insulin receptor expression by "'54% with B7, 75% with B10, and 40% with Bd ( Fig. 7 B) . Furthermore, 2'-amino R N A No. 1 protected cells from the autoantibodies in B10 serum as effectively as it protected cells from the MA20 mAb. By contrast, addition of the original 2'-amino pool R N A as a competitor did not inhibit the antigenic downmodulation engendered by the patient sera, indicating that 2'-amino R N A No. 1 specifically blocks the antiinsulin receptor autoantibodies in these sera. In addition, 2'-amino R N A No. 1 did not inhibit insulin-induced loss (34) o f insulin receptors on IM-9 cells (Fig. 7 B) . Thus, 2'-amino R N A No. 1 can block an autoimmune response to the insulin receptor without impeding insulin binding to its receptor. Finally, to determine how effectively 2'-amino R N A No. 1 could protect IM-9 cells from the autoantibodies present in the serum o f patient B10, a dose-escalation experiment was performed. As shown in Fig. 7 C, at high concentrations, 2'-amino R N A No. 1 can block ,'~70-80% of the B10 autoantibodies responsible for insulin receptor loss. Such protection is dose dependent with an EDs0 of"~ p~M (Fig.  7 C) . Therefore, 2'-amino R N A No. 1 can protect IM-9 cells from a significant fraction of the antiinsulin receptor autoantibodies present in a patient with severe insulin resistance.
D i s c u s s i o n
Previously, we and others have described the isolation of small R N A molecules that avidly bind specific antibodies and block them from binding their natural antigens in vitro (13, 14, 18) . These observations have led to the speculation that such R N A decoys may be useful as therapeutics to combat autoimmune responses in patients. While these initial studies allowed for much conjecture, they were unable to critically test many aspects of this decoy hypothesis. Specifically, the short half-life of R N A s in the presence o f se- . Downmodulation of insulin receptor expression was assayed by 12sI-insulin binding, as previously described. Values are expressed as a percentage of the downr u m nucleases made it impossible to determine if a decoy R N A could protect h u m a n cells from a patient's autoantibodies. T o address this shortcoming, we performed the experiments described herein.
In vitro selection techniques (4, 35, 36) were used to identify a small, nuclease-resistant R N A molecule that binds to a mouse mAb, called MA20, which naturally recognizes the main autoantigenic epitope on the h u m a n insulin receptor. T o yield nuclease-resistant R N A , selection was performed using a modified R N A pool containing pyrimidine nucleotides with 2 ' -a m i n o groups (27) . The selected R N A binds to the M A 2 0 antibody specifically (Fig.  1 ) and with high affinity (Fig. 3) . T h e presence of such 2 ' -a m i n o groups increased the stability of the R N A in ser u m by more than 10,000-fold, as compared to unmodified R N A (Fig. 4) . This selected R N A can serve as a decoy and block M A 2 0 b i n d i n g to insulin receptors on the surface of h u m a n lymphocytes (Fig. 5) . This R N A can also protect cells from the M A 2 0 antibody and prevent M A 2 0 -m e d iated d o w n m o d u l a t i o n of insulin receptor expression (Fig.  6) . Furthermore, this selected R N A cross-reacts with autoantibodies from three patients with extreme insulin resistance (type B) and can inhibit autoantibody-mediated d o w nmodulation of insulin receptor expression without impeding insulin b i n d i n g to its receptor (Fig. 7) . Thus, a nucleaseresistant decoy R N A can protect h u m a n cells from patient autoantibodies.
T h e three sets of h u m a n a u t o i m m u n e sera contain antibodies that naturally recognize the same region of the h um a n insulin receptor as MA20. This i m m u n o g e n i c region is contained within amino acids 450-601 of the ci subunit o f insulin receptor and appears to elicit the majority o f autoantibodies in patients with extreme insulin resistance (26) . Since small R N A s , selected to b i n d MA20, crossreact with autoantibodies that recognize the same epitope on insulin receptor as M A 2 0 (18 and Fig. 7 A) , we hypothesized that such selected R N A s may mimic the structure of the receptor that is b o u n d by the antibodies. Such R N A rnimotopes w o u l d be expected to be able to block a significant fraction of a patient's autoantibodies even though the patient's i m m u n e response to the antigenic epitope would probably be oligoclonal. As s h o w n in Fig. 7 B, selected 2 ' -a m i n o R N A No. 1 can significantly block the action of autoantibodies from three different patients, but to varying degrees. These different levels of inhibition may be caused by differences in the patient's i m m u n e response to the inmodulation engendered by the MA20 antibody (1 nM; percent of antigenic modulation), and the dilutions of patient sera used were chosen because they engender similar levels of downmodulation as 1 nM MA20 (see Materials and Methods for details). Values shown are means +-SD of three measurements obtained from three separate experiments. (C) IM-9 cells were incubated in culture media containing BI0 patient sera (1 p~l of 1:12 dilution) and increasing amounts of 2'-amino RNA No. 1, and downmodulation of insulin receptor expression was assayed as above. Values are expressed as the percentage of the downmodulation engendered by B10 patient sera alone. sulin receptor, with certain patients making a greater percentage of their autoantibodies against the main immunogenic region than others. In the best case, the RNA decoy appears to be able to inhibit the downmodulation of insulin receptor expression that is engendered by the autoantibodies from patient B10, as effectively as it inhibits the MA20 mAb (Fig. 7, B and C) . Thus, remarkably a single RNA decoy can apparently impede a significant fraction of a patient's autoantibodies from binding their targeted self-antigen. This result suggests that one or a few selected decoy RNAs may be able to block autoimmune responses, even though such responses are probably oligoclonal in nature.
The decoy RNA does not appear to inhibit insulin binding to and down-regulation of its receptor on the surface of human lymphocytes (Fig. 7 B) . This observation that the decoy RNA selectively blocks antibodies is consistent with the hypothesis that the RNA mimics the structure of the immunogenic epitope on the insulin receptor. MA20 has been shown to bind the receptor near but not at the site of insulin binding (23) . Thus, a decoy RNA that structurally resembles the antigenic region of the insulin receptor would not be expected to interact with insulin.
Our results suggest that designer decoy RNAs may become useful reagents to inhibit autoimmune responses. To be of any therapeutic value however, more effective RNA decoys will probably be required. To isolate an RNA decoy that can block a greater fraction of autoantibodies from a variety of patients, in vitro selections can be performed using a pool of human autoantibodies. Furthermore, it remains to be determined if nuclease-resistant decoy RNAs can block immune responses in animals or if they will elicit immune responses rather than block them.
